Paratek Completes Submission of New Drug Applications to U.S. FDA for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections

BOSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that on February 2, 2018, it completed the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news